|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Microfluidizer Á¾ÇÕÄ«´Ù·Î±× |
Phone |
|
|
  ´ëÇ¥ÀüÈ |
1577-7956   |
  º»     »ç |
031-457-9187   |
  ´ë     Àü |
042-932-1265 |
|
|
Web Site Visitors |
|
|
  Today |
492     |
  Yesterday |
629     |
  Since 2006 |
1,927,070     |
|
|
|
|
¿µÁøÄÚÆÛ·¹ÀÌ¼Ç Á¾ÇÕÄ«´Ù·Î±× |
|
|
Propofol Àº È¿°ú¿Í ȸº¹¼Óµµ°¡ ºü¸£¸ç ºÎÀÛ¿ëµµ ÀÛÀº ÀÏÁ¾ÀÇ Á¤¸Æ ¸¶ÃëÁ¦ÀÌ´Ù.
Propofol Àº ÁøÁ¤¿ë ¼ö¸éÁ¦ ¸ñÀûÀ¸·Îµµ ³Î¸® »ç¿ëµÇ°í Àִµ¥ ¿¹¸¦ µé¾î
ÁýÁßÄ¡·á½Ç¿¡¼ ÀΰøÈ£Èí±â¸¦ ºÎÂøÇÏ¿´°Å³ª ÁøÁ¤ÀÌ ÇÊ¿äÇÑ È¯Àڵ鿡°Ô Åõ¿©µÇ°í ÀÖ´Ù.
Propofol Àº ±Û·Î¹ú Äڷγª pandemic »óȲ¿¡¼ ´õ¿í ÁÖ¸ñÀ» ¹Þ°í ÀÖ´Ù.
Àå±âÀûÀ¸·Î ÀΰøÈ£Èí±â¸¦ ÇÊ¿ä·Î Çϰųª ÇÕº´ÁõÀÌ ½ÉÇÑ COVID-19 ȯÀڵ鿡°Ô
Propofol ó¹æÀÌ ±Þ¼ÓÈ÷ Áõ°¡ÇÏ´Â »óȲÀÌ´Ù.
ÀÌ Application Note ¿¡¼´Â ÀÌ Propofol À» ¾ÈÀüÇÏ°Ô »ý»êÇϴµ¥ ÀÖ¾î
Microfluidizer Technology °¡ ¾î¶»°Ô ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ÇÏ´ÂÁö µé¿©´Ù º¸°íÀÚ ÇÑ´Ù.
INTRODUCTION
Propofol Àº Àü¼¼°èÀûÀ¸·Î ¾ÆÁÖ ´Ù¾çÇÑ ºê·£µå¸íÀ¸·Î ÆǸŵǰí Àִµ¥
±× Áß¿¡¼ ¹Ì±¹ Fresenius Kabi »çÀÇ Diprivan Á¦Ç°ÀÌ °¡Àå Àß ¾Ë·ÁÁ® ÀÖ°í
³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç ÀϹÝÀûÀ¸·Î ¼ö¸é¸¶Ãë¿Í ÁøÁ¤Ä¡·á ¸ñÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ´Ù.
Propofol Àº soybean oil (´ëµÎÀ¯) ´Üµ¶ ¶Ç´Â soybean oil °ú medium chain triglycerides (MCT) ÀÇ
1:1 È¥ÇÕÇÑ ¿ÀÀÏÀ» carrier oil (10mg/ml) ·Î »ç¿ëÇϸç ÀÌ carrier oil °ú ´Ù¸¥ ¾àÇ°À» formulation ÇÏ¿© ¸¸µç lipid emulsion ÀÌ´Ù.
»ó¾÷ÀûÀ¸·Î Á¦Á¶µÇ´Â Á¤¸Æ emulsion Àº oil droplet ÀÇ Å©±â°¡ ¸ñǥġ À̳»À̾î¾ß ÇÏ°í ¶ÇÇÑ Å©±âºÐÆ÷°¡ ÀÏÁ¤ÇØ¾ß ÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÏ´Ù.
ÀϹÝÀûÀ¸·Î Á¤¸ÆÁֻ翡 »ç¿ëµÇ´Â emulsion ÀÇ Å©±â´Â Æò±Õ 150 - 300 nm Àε¥ propofol µµ ÀÌ ¹üÁÖ¿¡ µé¾î¿Í¾ß ÇÑ´Ù.
¿¹¸¦ µé¾î Diprivan µµ intensity based mean droplet diameter °¡ ¾à 160 - 180 nm ÀÌ´Ù.
¶ÇÇÑ droplet Å©±â°¡ ±ÕÀÏÇÑ °ÍÀÌ ¸Å¿ì Áß¿äÇѵ¥ ÀÌ´Â emulsion ÀÇ Àå±â º¸°ü¿¡ ¸Å¿ì Å« ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®ÀÌ´Ù.
THE SOLUTION
Microfluidizer Technology ´Â Å©±â°¡ ¸Å¿ì ±ÕÀÏÇÑ nanoemulsion À» Á¦Á¶Çϴµ¥ ¸Å¿ì È¿°úÀûÀ̶ó´Â »ç½ÇÀÌ Àß Áõ¸íµÈ ±â¼úÀÌ´Ù.
ÀÌ ±â¼úÀº ½Å·Ú¼ºÀÌ ÀÖÀ¸¸ç ¶ÇÇÑ ½ÇÇè´Ü°è¿¡¼ »ý»ê´Ü°è·ÎÀÇ scale up ÀÌ ¸Å¿ì ¼Õ½±°Ô ÀÌ·ç¾î Áø´Ù´Â Ư¡ÀÌ ÀÖ´Ù.
¶ÇÇÑ Microfluidizer ºÐ»êÀåºñ´Â cGMP ±ÔÁ¤¿¡ ¿Ïº®È÷ ºÎÇÕÇÏ¿© »ó¾÷¿ë Bio-Pharma Á¦Ç° »ý»ê¿¡ °¡Àå ÀûÇÕÇÑ ÀåºñÀÌ´Ù.
CASE STUDY
Microfluidizer Technology °¡ Propofol emulsion »ý»ê¿¡¼ ¾î´À Á¤µµ È¿À²¼ºÀÌ ÀÖ´ÂÁö Å×½ºÆ® ÇÏ¿´À¸¸ç
À̸¦ À§ÇØ Diprivan °ú À¯»çÇÑ propofol formulation À» Microfluidizer °í¾ÐºÐ»êÀåºñ¸¦ ÀÌ¿ëÇÏ¿© À¯Èó¸®ÇÏ¿´´Ù.
RESULTS
Figure 1 - Emulsion before and after being processed through a Microfluidizer processor
Çö¹Ì°æ »çÁø (figure 1.) °ú Å×À̺íÀÇ particle size ¿¡¼ º¸µíÀÌ, Microfluidizer ¿¡¼ 20,000psi ¾Ð·ÂÀ¸·Î ó¸®ÇÑ °á°ú
droplet Àº Å©±â°¡ ¸Å¿ì ÀÛÀ¸¸ç ¶ÇÇÑ Å©±â°¡ ¸Å¿ì ±ÕÀÏÇÏ¿´´Ù.
20,000psi ¾Ð·Â¿¡¼ 1 pass ÇÏ¿´À» ¶§ d50 ÀÔµµ´Â ¾à 170 nm À̾ú´Âµ¥ ÀÌ °ªÀº refernce °ª°ú À¯»çÇÏ¿´À¸¸ç
¶ÇÇÑ d10, d50 ±×¸®°í d90 ÀÇ ÀÔµµºÐÆ÷ ¿ª½Ã reference ¿Í À¯»çÇÏ¿´´Ù.
2 pass ¸¦ ÇÏ¿´À» ¶§ÀÇ d50 ¿¡¼ÀÇ ÀÔÀÚÅ©±â´Â 140nm ·Î ³»·Á°¬´Ù.
´Ù¸¥ ÁÖ»çÁ¦ ÀǾàÇ°°ú °°ÀÌ propofol emulsion Àº ¹Ì»ý¹° ¿À¿°À» ¹æÁöÇϱâ À§ÇØ ¸ê±ÕÀ» ÇÏ¿©¾ßÇÑ´Ù.
propofol Àº °í¿Â¿¡¼ ¸Å¿ì ¾ÈÁ¤ÇϹǷΠautoclave °¡ °¡´ÉÇÏ´Ù.
À§ Å×ÀÌºí¿¡¼ d90 ¿¡¼ÀÇ droplet Æò±Õ Å©±â°¡ 220nm À̹ǷΠÀÌ emulsion Àº autoclave °¡ ¾Æ´Ñ
sterile filteration À» ÀÌ¿ëÇÏ¿© ¸ê±ÕÇÑ °ÍÀÌ´Ù.
SCALABILITY
½ÇÇè´Ü°è¿¡¼ ±¸ÇÑ Å×½ºÆ® °á°ú´Â »ý»ê´Ü°è¿¡¼ ±¸ÇÑ Á¦Ç°ÀÇ Ç°Áú °á°ú¿Í µ¿ÀÏÇϹǷΠMicrolfuidizer Technology ´Â
scalability °¡ Ź¿ùÇÏ´Ù ÇÒ ¼ö ÀÖ´Ù.
Figure 2 - Comparison of particle size distribution obtained from pilot scale and production scale Microfluidizer processor
Figure 2 ´Â pilot scale ÀåºñÀÎ 110EH ¿¡¼ ±¸ÇÑ °á°ú¿Í »ý»ê¿ëÀåºñÀÎ M7250-30 À» ÀÌ¿ëÇÑ °á°ú¸¦ ºñ±³ÇÑ °ÍÀÌ´Ù.
»ý»ê¿ë Àåºñ¿¡¼ 1 pass, 2 pass ÇÑ °á°ú´Â pilot scale Àåºñ¿¡¼ ±¸ÇÑ °á°ú¿Í ¸Å¿ì À¯»çÇÏ´Ù´Â °ÍÀ» È®ÀÎÇÒ ¼ö ÀÖ´Ù.
Áï ÀÔÀÚÅ©±â¿Í ÀÔµµºÐÆ÷°¡ °ÅÀÇ À¯»çÇÏ´Ù´Â °ÍÀ» ¾Ë ¼ö ÀÖ´Ù.
|
|
|
|